Real-world evidence of the management and prognosis of young women (≤40 years) with de novo metastatic breast cancer

被引：3

作者：

Mallet, Amelie ^{[1
]}

Lusque, Amelie ^{[2
]}

Levy, Christelle ^{[3
]}

Pistilli, Barbara ^{[4
]}

Brain, Etienne ^{[5
]}

Pasquier, David ^{[6
]}

Debled, Marc ^{[7
]}

Thery, Jean Christophe ^{[8
]}

Goncalves, Anthony ^{[9
]}

Desmoulins, Isabelle ^{[10
]}

Rouge, Thibault De La Motte ^{[11
]}

Faure, Christelle ^{[12
]}

Ferrero, Jean Marc ^{[13
]}

Eymard, Jean Christophe ^{[14
]}

Mouret-Reynier, Marie Ange ^{[15
]}

Patsouris, Anne ^{[16
]}

Cottu, Paul ^{[17
]}

Dalenc, Florence ^{[18
]}

Petit, Thierry ^{[19
]}

Payen, Olivier ^{[20
]}

Uwer, Lionel ^{[21
]}

Guiu, Severine ^{[22
]}

Frenel, Jean Sebastien ^{[1
]}

机构：

[1] Inst Cancerol Ouest Rene Gauducheau, Dept Med Oncol, Blvd Jacques Monod, F-44805 St Herblain, France

[2] IUCT Oncopole, Dept Biostat, Inst Claudius Regaud, Toulouse, France

[3] Ctr Francois Baclesse, Dept Med Oncol, Caen, France

[4] Gustave Roussy, Dept Canc Med, Villejuif, France

[5] Inst Curie, Dept Med Oncol, Paris, France

[6] Ctr Oscar Lambret, Dept Radiat Oncol, Lille, France

[7] Inst Bergonie, Dept Med Oncol, Bordeaux, France

[8] Ctr Henri Becquerel, Dept Med Oncol, Rouen, France

[9] Inst Paoli Calmettes, Dept Med Oncol, Marseille, France

[10] Ctr Georges Francois Leclerc, Dept Med Oncol, Dijon, France

[11] Ctr Eugene Marquis, Dept Med Oncol, Rennes, France

[12] Ctr Leon Berard, Dept Surg Oncol, Lyon, France

[13] Ctr Antoine Lacassagne, Dept Med Oncol, Nice, France

[14] Inst Cancerol Jean Godinot, Dept Med Oncol, Reims, France

[15] Ctr Jean Perrin, Dept Med Oncol, Clermont Ferrand, France

[16] Inst Cancerol Ouest Paul Papin, Dept Med Oncol, Angers, France

[17] Etab Hosp Inst Curie, Dept Med Oncol, Paris, France

[18] Inst Claudius Regaud, Dept Med Oncol, IUCT Oncopole, Toulouse, France

[19] Ctr Paul Strauss, Dept Med Oncol, Strasbourg, France

[20] UNICANCER, Data Unit, Dept Real World Data, Paris, France

[21] Inst Cancerol Lorraine, Dept Med Oncol, Vandoeuvre Les Nancy, France

[22] Inst Canc Montpellier, Dept Med Oncol, Montpellier, France

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2022年 / 14卷

关键词：

de novo; metastatic breast cancer; prognosis; real-life; young women; PRIMARY TUMOR; SURVIVAL; METAANALYSIS; GUIDELINES; DOCETAXEL; SURGERY; THERAPY;

D O I：

10.1177/17588359211070362

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Breast cancer (BC) in young women merits a specific approach given the associated fertility, genetic and psychosocial issues. De novo metastatic breast cancer (MBC) in young women is an even more serious condition, with limited data available. Methods: We evaluated management of women aged <= 40 years with de novo MBC in a real-life national multicentre cohort of 22,463 patients treated between 2008 and 2016 (NCT0327531). Our primary objective was to compare overall survival (OS) in young women versus women aged 41-69 years. The secondary objectives were to compare first-line progression-free survival (PFS1) and to describe treatment patterns. Results: Of the 4524 women included, 598 (13%) were <= 40 years. Median age at MBC diagnosis was 36 years (range = 20-40). Compared with women aged 41-69 years, young women had more grade III tumours (49% versus 35.7%, p < 0.0001), human epidermal growth factor receptor 2 amplified (HER2+) disease (34.6% versus 26.4%, p < 0.0001) and HR-/HER2- disease known as "triple negative breast cancer" (TNBC) (17.1% versus 12.7%, p < 0.0001). BRCA testing was performed for 260 young women, with a BRCA1/2 mutation in 44 (17% of those tested) In young HR+/HER2- patients, chemotherapy (CT) was given as the frontline treatment more frequently compared with older ones (89.6% versus 68.8%, respectively, p < 0.0001). After median follow-up of 49.7 months (95% confidence interval, CI = 48.0-51.7), the median OS of young women was 58.5 months, 20.7 months and not attained in HR+/HER2-, TNBC and HER2+ subgroups, respectively. After adjustment for histological subtype, tumour grade, and number and type of metastasis, young women had significantly better OS compared with older ones, except for the TNBC subgroup, for which the outcome was similar. PFS1 was statistically different only in the TNBC subgroup, with 7.8 months for young women and 6.3 months for older women (p = 0.0015). Conclusion: De novo MBC affects a significant proportion of young women. A subgroup of these patients achieves long OS and merits multidisciplinary care.

引用

页数：15

共 33 条

[21] Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer [J].

Im, S. -A. ;

Lu, Y. -S. ;

Bardia, A. ;

Harbeck, N. ;

Colleoni, M. ;

Franke, F. ;

Chow, L. ;

Sohn, J. ;

Lee, K. -S. ;

Campos-Gomez, S. ;

Villanueva-Vazquez, R. ;

Jung, K. -H. ;

Chakravartty, A. ;

Hughes, G. ;

Gounaris, I. ;

Rodriguez-Lorenc, K. ;

Taran, T. ;

Hurvitz, S. ;

Tripathy, D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (04) :307-316

[22] Incidence of Breast Cancer With Distant Involvement Among Women in the United States, 1976 to 2009 [J].

Johnson, Rebecca H. ;

Chien, Franklin L. ;

Bleyer, Archie .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (08) :800-805

[23] Younger age as a prognostic indicator in breast cancer: A cohort study [J].

Kheirelseid, Elrasheid A. H. ;

Boggs, Jennifer M. E. ;

Curran, Catherine ;

Glynn, Ronan W. ;

Dooley, Cara ;

Sweeney, Karl J. ;

Kerin, Michael J. .

BMC CANCER, 2011, 11

[24] Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL [J].

Martin, M. ;

Zielinski, C. ;

Ruiz-Borrego, M. ;

Carrasco, E. ;

Turner, N. ;

Ciruelos, E. M. ;

Munoz, M. ;

Bermejo, B. ;

Margeli, M. ;

Anton, A. ;

Kahan, Z. ;

Csoszi, T. ;

Casas, M., I ;

Murillo, L. ;

Morales, S. ;

Alba, E. ;

Gal-Yam, E. ;

Guerrero-Zotano, A. ;

Calvo, L. ;

de la Haba-Rodriguez, J. ;

Ramos, M. ;

Alvarez, I ;

Garcia-Palomo, A. ;

Bartlett, C. Huang ;

Koehler, M. ;

Caballero, R. ;

Corsaro, M. ;

Huang, X. ;

Garcia-Saenz, J. A. ;

Chacon, J., I ;

Swift, C. ;

Thallinger, C. ;

Gil-Gil, M. .

ANNALS OF ONCOLOGY, 2021, 32 (04) :488-499

[25] Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group [J].

Marty, M ;

Cognetti, F ;

Maraninchi, D ;

Snyder, R ;

Mauriac, L ;

Tubiana-Hulin, M ;

Chan, S ;

Grimes, D ;

Antón, A ;

Lluch, A ;

Kennedy, J ;

O'Byrne, K ;

Conte, P ;

Green, M ;

Ward, C ;

Mayne, K ;

Extra, JM .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (19) :4265-4274

[26] Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer [J].

Ogiya, Rin ;

Sagara, Yasuaki ;

Niikura, Naoki ;

Freedman, Rachel A. .

CLINICAL BREAST CANCER, 2019, 19 (03) :200-+

[27] ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4) [J].

Paluch-Shimon, S. ;

Cardoso, F. ;

Partridge, A. H. ;

Abulkhair, O. ;

Azim, H. A., Jr. ;

Bianchi-Micheli, G. ;

Cardoso, M-J ;

Curigliano, G. ;

Gelmon, K. A. ;

Harbeck, N. ;

Merschdorf, J. ;

Poortmans, P. ;

Pruneri, G. ;

Senkus, E. ;

Spanic, T. ;

Stearns, V ;

Wengstrom, Y. ;

Peccatori, F. ;

Pagani, O. .

ANNALS OF ONCOLOGY, 2020, 31 (06) :674-696

[28] The Evolving Role of FDG-PET/CT in the Diagnosis, Staging, and Treatment of Breast Cancer [J].

Paydary, Koosha ;

Seraj, Siavash Mehdizadeh ;

Zadeh, Mahdi Zirakchian ;

Emamzadehfard, Sahra ;

Shamchi, Sara Pourhassan ;

Gholami, Saeid ;

Werner, Thomas J. ;

Alavi, Abass .

MOLECULAR IMAGING AND BIOLOGY, 2019, 21 (01) :1-10

[29] Surgery of primary tumors in stage IV breast cancer: an updated meta-analysis of published studies with meta-regression [J].

Petrelli, Fausto ;

Barni, Sandro .

MEDICAL ONCOLOGY, 2012, 29 (05) :3282-3290

[30] Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis [J].

Reinhorn, Daniel ;

Mutai, Raz ;

Yerushalmi, Rinat ;

Moore, Assaf ;

Amir, Eitan ;

Goldvaser, Hadar .

BREAST, 2021, 58 :173-181

← 1 2 3 4 →